Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia
Copyright © 2013 IBRO. All rights reserved..
The 5-HT (5-hydroxytryptamine) system has been assigned a key role in the development of 3,4-dihydroxyphenyl-l-alanine (l-DOPA)-induced dyskinesia, mainly due to 5-HT neuronal ability to decarboxylate l-DOPA into dopamine. Nevertheless, knowledge of l-DOPA-induced events that could lead to development of dyskinesias are limited and therefore the present work has evaluated (i) the role of the 5-HT system in l-DOPA-derived dopamine synthesis when dopamine neurons are present, (ii) l-DOPA-induced effects on striatal dopamine release and clearance, and on 5-HT nerve fiber density, and (iii) the behavioral outcome of altered 5-HT transmission in dyskinetic rats. Chronoamperometric recordings demonstrated attenuated striatal l-DOPA-derived dopamine release (∼30%) upon removal of 5-HT nerve fibers in intact animals. Interestingly, four weeks of daily l-DOPA treatment yielded similar-sized dopamine peak amplitudes in intact animals as found after a 5-HT-lesion. Moreover, chronic l-DOPA exposure attenuated striatal 5-HT nerve fiber density in the absence of dopamine nerve terminals. Furthermore, fluoxetine-induced altered 5-HT transmission blocked dyskinetic behavior via action on 5-HT1A receptors. Taken together, the results indicate a central role for the 5-HT system in l-DOPA-derived dopamine synthesis and in dyskinesia, and therefore potential l-DOPA-induced deterioration of 5-HT function might reduce l-DOPA efficacy as well as promote the upcoming of motor side effects.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2014 |
|---|---|
| Erschienen: |
2014 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:260 |
|---|---|
| Enthalten in: |
Neuroscience - 260(2014) vom: 28. Feb., Seite 73-86 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Nevalainen, N [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.09.2014 Date Revised 03.02.2014 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.neuroscience.2013.12.029 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM233887199 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM233887199 | ||
| 003 | DE-627 | ||
| 005 | 20231224100053.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231224s2014 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.neuroscience.2013.12.029 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n0779.xml |
| 035 | |a (DE-627)NLM233887199 | ||
| 035 | |a (NLM)24361918 | ||
| 035 | |a (PII)S0306-4522(13)01045-2 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Nevalainen, N |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Serotonergic nerve fibers in L-DOPA-derived dopamine release and dyskinesia |
| 264 | 1 | |c 2014 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.09.2014 | ||
| 500 | |a Date Revised 03.02.2014 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2013 IBRO. All rights reserved. | ||
| 520 | |a The 5-HT (5-hydroxytryptamine) system has been assigned a key role in the development of 3,4-dihydroxyphenyl-l-alanine (l-DOPA)-induced dyskinesia, mainly due to 5-HT neuronal ability to decarboxylate l-DOPA into dopamine. Nevertheless, knowledge of l-DOPA-induced events that could lead to development of dyskinesias are limited and therefore the present work has evaluated (i) the role of the 5-HT system in l-DOPA-derived dopamine synthesis when dopamine neurons are present, (ii) l-DOPA-induced effects on striatal dopamine release and clearance, and on 5-HT nerve fiber density, and (iii) the behavioral outcome of altered 5-HT transmission in dyskinetic rats. Chronoamperometric recordings demonstrated attenuated striatal l-DOPA-derived dopamine release (∼30%) upon removal of 5-HT nerve fibers in intact animals. Interestingly, four weeks of daily l-DOPA treatment yielded similar-sized dopamine peak amplitudes in intact animals as found after a 5-HT-lesion. Moreover, chronic l-DOPA exposure attenuated striatal 5-HT nerve fiber density in the absence of dopamine nerve terminals. Furthermore, fluoxetine-induced altered 5-HT transmission blocked dyskinetic behavior via action on 5-HT1A receptors. Taken together, the results indicate a central role for the 5-HT system in l-DOPA-derived dopamine synthesis and in dyskinesia, and therefore potential l-DOPA-induced deterioration of 5-HT function might reduce l-DOPA efficacy as well as promote the upcoming of motor side effects | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 5,7-DHT | |
| 650 | 4 | |a 5,7-dihydroxytryptamine | |
| 650 | 4 | |a 5-HT | |
| 650 | 4 | |a 6-OHDA | |
| 650 | 4 | |a 6-hydroxydopamine | |
| 650 | 4 | |a AIM | |
| 650 | 4 | |a ANOVA | |
| 650 | 4 | |a LGE | |
| 650 | 4 | |a LID | |
| 650 | 4 | |a PBS | |
| 650 | 4 | |a SERT | |
| 650 | 4 | |a Serotonin | |
| 650 | 4 | |a TH | |
| 650 | 4 | |a WAY-100 635 | |
| 650 | 4 | |a abnormal involuntary movement | |
| 650 | 4 | |a analysis of variance | |
| 650 | 4 | |a dyskinesia | |
| 650 | 4 | |a fluoxetine | |
| 650 | 4 | |a in vivo chronoamperometry | |
| 650 | 4 | |a l-DOPA | |
| 650 | 4 | |a l-DOPA-induced dyskinesia | |
| 650 | 4 | |a lateral ganglionic eminence | |
| 650 | 4 | |a phosphate-buffered saline | |
| 650 | 4 | |a serotonin transporter | |
| 650 | 4 | |a tyrosine hydroxylase | |
| 650 | 7 | |a Serotonin Plasma Membrane Transport Proteins |2 NLM | |
| 650 | 7 | |a Slc6a4 protein, rat |2 NLM | |
| 650 | 7 | |a Fluoxetine |2 NLM | |
| 650 | 7 | |a 01K63SUP8D |2 NLM | |
| 650 | 7 | |a Levodopa |2 NLM | |
| 650 | 7 | |a 46627O600J |2 NLM | |
| 650 | 7 | |a Dopamine |2 NLM | |
| 650 | 7 | |a VTD58H1Z2X |2 NLM | |
| 700 | 1 | |a Af Bjerkén, S |e verfasserin |4 aut | |
| 700 | 1 | |a Gerhardt, G A |e verfasserin |4 aut | |
| 700 | 1 | |a Strömberg, I |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuroscience |d 1976 |g 260(2014) vom: 28. Feb., Seite 73-86 |w (DE-627)NLM000132403 |x 1873-7544 |7 nnns |
| 773 | 1 | 8 | |g volume:260 |g year:2014 |g day:28 |g month:02 |g pages:73-86 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.neuroscience.2013.12.029 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 260 |j 2014 |b 28 |c 02 |h 73-86 | ||